These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 29245013)

  • 1. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.
    Palmer AC; Sorger PK
    Cell; 2017 Dec; 171(7):1678-1691.e13. PubMed ID: 29245013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additivity predicts the efficacy of most approved combination therapies for advanced cancer.
    Hwangbo H; Patterson SC; Dai A; Plana D; Palmer AC
    Nat Cancer; 2023 Dec; 4(12):1693-1704. PubMed ID: 37974028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent Drug Action in Combination Therapy: Implications for Precision Oncology.
    Plana D; Palmer AC; Sorger PK
    Cancer Discov; 2022 Mar; 12(3):606-624. PubMed ID: 34983746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level.
    Vis DJ; Jaaks P; Aben N; Coker EA; Barthorpe S; Beck A; Hall C; Hall J; Lightfoot H; Lleshi E; Mironenko T; Richardson L; Tolley C; Garnett MJ; Wessels LFA
    Cell Rep Med; 2024 Aug; 5(8):101687. PubMed ID: 39168097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?
    Perez-Gracia JL; Berraondo P; Martinez-Forero I; Alfaro C; Suarez N; Gurpide A; Sangro B; Hervas-Stubbs S; Ochoa C; Melero JA; Melero I
    Immunotherapy; 2009 Sep; 1(5):845-53. PubMed ID: 20636027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs.
    Teicher BA
    Curr Opin Pharmacol; 2010 Aug; 10(4):397-404. PubMed ID: 20547104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
    Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
    Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls.
    Vlot AHC; Aniceto N; Menden MP; Ulrich-Merzenich G; Bender A
    Drug Discov Today; 2019 Dec; 24(12):2286-2298. PubMed ID: 31518641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
    Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
    Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.
    Chisholm RH; Lorenzi T; Clairambault J
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2627-45. PubMed ID: 27339473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.
    Palmer AC; Chidley C; Sorger PK
    Elife; 2019 Nov; 8():. PubMed ID: 31742555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
    Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
    Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
    Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
    Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors.
    Lorz A; Lorenzi T; Clairambault J; Escargueil A; Perthame B
    Bull Math Biol; 2015 Jan; 77(1):1-22. PubMed ID: 25480478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach.
    Rocchetti M; Del Bene F; Germani M; Fiorentini F; Poggesi I; Pesenti E; Magni P; De Nicolao G
    Eur J Cancer; 2009 Dec; 45(18):3336-46. PubMed ID: 19854637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design and identification of immuno-oncology drug combinations.
    Iafolla MAJ; Selby H; Warner K; Ohashi PS; Haibe-Kains B; Siu LL
    Eur J Cancer; 2018 May; 95():38-51. PubMed ID: 29631102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates.
    Poupon MF; Arvelo F; Goguel AF; Bourgeois Y; Jacrot M; Hanania N; Arriagada R; Le Chevalier T
    J Natl Cancer Inst; 1993 Dec; 85(24):2023-9. PubMed ID: 7902445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.